Incyte (INCY) Change in Receivables (2010 - 2026)
Incyte's (INCY) quarterly Change in Receivables came in at $73.8 million in Q2 2026, up 264.8% YoY from $20.2 million in Q2 2025, and up 173.04% on a QoQ basis from $27.0 million in Q1 2026.
Incyte (INCY) Change in Receivables (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Change in Receivables data on file, last reported at $73.8 million in Q2 2026.
- Quarterly Change in Receivables rose 264.8% year-over-year to $73.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $282.3 million (up 167.94% YoY) and the FY2025 annual result came in at $170.8 million, up 53.04% from the prior year.
- Change in Receivables climbed to $73.8 million in Q2 2026, from $27.0 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $128.5 million in Q4 2025 to a low of -$64.8 million in Q3 2022.
- A 5-year average of $28.4 million and a median of $19.8 million in 2024 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 412.37% in 2025, down 1672.12% in 2025.
- Tracing INCY's Change in Receivables over 5 years: stood at $26.7 million in 2022, then jumped by 223.31% to $86.3 million in 2023, then gained by 12.05% to $96.7 million in 2024, then jumped by 32.89% to $128.5 million in 2025, then slumped by 42.57% to $73.8 million in 2026.
- The last three Change in Receivables figures came in at $73.8 million (Q2 2026), $27.0 million (Q1 2026), and $128.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 73.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.80 Mn |
| Jun 30, 2026 | 73.80 Mn |
| Mar 31, 2026 | 27.03 Mn |
| Mar 31, 2026 | 27.03 Mn |
| Dec 31, 2025 | 128.50 Mn |
| Dec 31, 2025 | 128.50 Mn |
| Sep 30, 2025 | 53.00 Mn |
| Sep 30, 2025 | 53.00 Mn |
| Jun 30, 2025 | 20.23 Mn |
| Jun 30, 2025 | 20.23 Mn |
| Mar 31, 2025 | -30.96 Mn |
| Mar 31, 2025 | -30.96 Mn |
| Dec 31, 2024 | 96.69 Mn |
| Dec 31, 2024 | 96.69 Mn |
| Sep 30, 2024 | 19.40 Mn |
| Sep 30, 2024 | 19.40 Mn |
| Jun 30, 2024 | -6.48 Mn |
| Jun 30, 2024 | -6.48 Mn |
| Mar 31, 2024 | 1.97 Mn |
| Mar 31, 2024 | 1.97 Mn |